Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8<sup>+</sup> T cells via ME1 up-regulation.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37967193.
- Also identified by DOI 10.1126/sciadv.adi2414 and PMC identifier 10651128.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with advanced cancers who either do not experience initial response to or progress while on immune checkpoint inhibitors (ICIs) receive salvage radiotherapy to reduce tumor burden and tumor-related symptoms. Occasionally, some patients experience substantial global tumor regression with a rebound of cytotoxic CD8<sup>+</sup> T cells. We have termed the rebound of cytotoxic CD8<sup>+</sup> T cells in response to salvage therapy as T cell resilience and examined the underlying mechanisms of resilience. Resilient T cells are enriched for CX3CR1<sup>+</sup> CD8<sup>+</sup> T cells with low mitochondrial membrane potential, accumulate less reactive oxygen species (ROS), and express more malic enzyme 1 (ME1). ME1 overexpression enhanced the cytotoxicity and expansion of effector CD8<sup>+</sup> T cells partially via the type I interferon pathway. ME1 also increased mitochondrial respiration while maintaining the redox state balance. ME1 increased the cytotoxicity of peripheral lymphocytes from patients with advanced cancers. Thus, preserved resilient T cells in patients rebound after salvage therapy and ME1 enhances their resiliency.
Medical subject headings
- Neoplasms
- Antineoplastic Agents